Leerink Partners Issues Positive Forecast for Edwards Lifesciences (NYSE:EW) Stock Price

Posted by Stanley Muller on Nov 5th, 2026

Edwards Lifesciences (NYSE:EW – Get Free Report) had its target price hoisted by analysts at Leerink Partners from $101.00 to $112.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Leerink Partners‘s price objective suggests a potential upside of 11.68% from the stock’s current price.

Several other research firms have also recently weighed in on EW. Rothschild & Co Redburn upped their price target on shares of Edwards Lifesciences from $99.00 to $102.00 and gave the company a “buy” rating in a report on Monday, July 27th. UBS Group restated a “buy” rating and set a $110.00 price objective (up from $90.00) on shares of Edwards Lifesciences in a report on Thursday, October 8th. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, October 27th. Citigroup reaffirmed a “buy” rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research note on Monday, October 5th. Finally, Mizuho set a $120.00 target price on Edwards Lifesciences in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $106.52.

Read Our Latest Research Report on EW

Edwards Lifesciences Trading Up 0.9%

NYSE EW traded up $0.92 during trading on Thursday, reaching $100.29. 5,753,558 shares of the stock traded hands, compared to its average volume of 4,514,993. Edwards Lifesciences has a fifty-two week low of $74.66 and a fifty-two week high of $104.17. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a market cap of $57.75 billion, a price-to-earnings ratio of 57.54, a price-to-earnings-growth ratio of 2.49 and a beta of 0.85. The stock’s 50-day moving average price is $88.48 and its 200 day moving average price is $85.61.

Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.06. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.72 billion for the quarter, compared to analyst estimates of $1.68 billion. During the same period last year, the business posted $0.67 earnings per share. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. Analysts predict that Edwards Lifesciences will post 3.00 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Annette Brüls sold 2,644 shares of the stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Andrew M. Dahl sold 544 shares of the firm’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the transaction, the senior vice president directly owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 5,045 shares of company stock valued at $451,596 over the last 90 days. 0.31% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of large investors have recently modified their holdings of EW. RMG Wealth Management LLC bought a new position in Edwards Lifesciences during the 1st quarter worth approximately $26,000. Pin Oak Investment Advisors Inc. bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $26,000. GK Wealth Management LLC bought a new position in Edwards Lifesciences in the third quarter worth approximately $26,000. TrinityBridge Ltd acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at $27,000. Finally, Meeder Asset Management Inc. grew its holdings in shares of Edwards Lifesciences by 175.2% during the first quarter. Meeder Asset Management Inc. now owns 366 shares of the medical research company’s stock valued at $29,000 after buying an additional 233 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

More Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

Positive Sentiment: Edwards reported third-quarter adjusted EPS of $0.80 and revenue of $1.72 billion, topping estimates. Sales grew 11.2% year over year, supported by 8.8% growth in TAVR and a 45.6% surge in transcatheter mitral and tricuspid therapies (TMTT). The company raised its full-year adjusted EPS outlook to $2.97–$3.05, reinforcing expectations for continued growth. Q3 earnings call highlights
Positive Sentiment: New PROGRESS Trial results found TAVR performed better than active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure outcomes, fewer heart-failure hospitalizations and improved quality of life. The findings could support earlier use of the procedure; the company also expects procedure volumes to benefit from expanded Medicare reimbursement. PROGRESS Trial data
Positive Sentiment: Several firms raised price targets after the results. Piper Sandler and BTIG set targets of $115, Baird upgraded EW to “outperform” with a $116 target, and JPMorgan raised its target to $120. These actions signal improved analyst expectations. JPMorgan price target change
Negative Sentiment: Management cautioned that more competition is coming in TAVR, which could pressure market share or pricing. RBC also said the PROGRESS findings may not meaningfully expand the TAVR market, tempering expectations for the trial’s commercial impact. CEO comments on TAVR competition

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.